Publication details

Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia

Authors

KRYUKOV Fedor DEMENTYEVA Elena Vladimirovna KUBICZKOVÁ Lenka JARKOVSKÝ Jiří BROŽOVÁ Lucie PETRÍK Jakub NĚMEC Pavel ŠEVČÍKOVÁ Sabina MINARIK Jiri STEFANIKOVA Zdena KUGLÍK Petr HÁJEK Roman

Year of publication 2013
Type Article in Periodical
Magazine / Source Genomics
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1016/j.ygeno.2013.06.007
Field Oncology and hematology
Keywords Multiple myeloma; Plasma cell leukemia; Cell cycle genes; Overall survival; Time-to-progression
Description The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight the presence of dynamic equilibrium between co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activator changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival was 30.3 +/- 3.9 months for 'low' expressed and 7.5 +/- 5.6 months for 'high' expressed group, p < 0.0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 +/- 3.6 months for 'low' and 8.4 +/- 2.7 months for 'high' expressed group, p < 0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 +/- 2.8 months for 'low' and 9.8 +/- 1.1 months for 'high' expressed group, p < 0.0001). The overexpression of inhibitors can be explained as a compensatory reaction to growing "oncogenic stress".
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info